Navigation Links
AEterna's acquisition of Zentaris being followed up with its new product pipeline and clinical development strategy

AEterna Laboratories Inc., a biopharmaceutical company focused on the development of novel therapeutic treatments in oncology and endocrinology recently acquired the new German based biopharmaceutical company, Zentaris AG. Following this acquisition// the new entity has in the pipeline six clinical stage products and two preclinical stage products, in oncology and one product already approved and marketed for in vitro fertilization in endocrinology. There are also two products in the preclinical stage and one in the clinical stage, in endocrinology.

AEterna's Chairman and CEO, Dr. Eric Dupont, believes that they now have the right partner to develop a leadership position in two growing therapeutic areas, oncology and endocrinology as Zentaris provides experienced management and drug development teams, an already marketed product, a solid financial position with a positive cash flow for 2002, eight additional global pharmaceutical partnerships and an impressive drug discovery platform.

AEterna's and Zentaris' combined clinical development strategy is based on five factors; development costs, competitive environment, involvement of pharmaceutical partners, time to market and potential markets for future drugs. The new structure is expected to drive drug discovery on an ongoing- forward basis through a state-of-the-art drug discovery unit, including a 100,000 proprietary compound library. Gilles Gagnon, President and COO at AEterna added that given the above five factors and and a portfolio of 12 products in development, the strategy for Neovastat will now strictly focus on the two ongoing Phase III studies in kidney cancer and lung cancer. Results of the kidney cancer trial are expected by the first or second quarter of 2003, while those of the lung cancer trial should be disclosed by the end of 2005.

Prof. Dr. Jurgen Engel, Chief Executive Officer at Zentaris concluded that the combined expertise will allow advancement of multiple pro mising preclinical and clinical projects for the development of novel treatments focused on oncology and endocrinology.


'"/>




Related medicine news :

1. NHS financial crisis may lead to roll back of flexi-work scheme and private acquisition
2. Are cancer patients being taken for a ride?
3. Nervous disorder being treated
4. Benign eye tumors being treated
5. Heart disease in women being under-treated
6. Chance of water births being urged for mums-to-be
7. CPR! How Effectively is it being done ?
8. Men tend to deny being overweight
9. Yoga, ayurveda being documented to stop patent misuse
10. Surgeons being paid triple the amount to cut waiting lists
11. Fund being raised for treatment to HIV positive Libyan kid
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/26/2016)... ... June 26, 2016 , ... On June 10-11, 2016, A ... 2016 Cereal Festival and World’s Longest Breakfast Table in Battle Creek, MI, where the ... history as home to some of the world’s leading providers of cereal and other ...
(Date:6/26/2016)... ... 2016 , ... PawPaws brand pet supplements owned by Whole Health ... the health of felines. The formula is all-natural and is made from Chinese herbs ... Cat Kidney Support Supplement Soft Chews are Astragalus Root Extract and Rehmannia ...
(Date:6/26/2016)... Lake Orion, Clarkston, Michigan (PRWEB) , ... June ... ... direction with respect to fertility once they have been diagnosed with endometriosis. These ... tolerable intercourse but they also require a comprehensive approach that can help for ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery ... of Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , ... for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey ...
(Date:6/25/2016)... ... , ... "With 30 hand-drawn hand gesture animations, FCPX users can easily customize ... Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn pictures into ... Simply select a ProHand generator and drag it above media or text in the ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... -- MedSource announced today that it has selected Datatrial,s ... choice.  This latest decision demonstrates MedSource,s commitment to ... by offering a state-of-the-art electronic data capture (EDC) ... the EDC platform of choice in exchange for ... long been a preferred EDC platform by our ...
(Date:6/23/2016)... -- Research and Markets has announced the ... (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality (Filler, ... Global Forecast to 2021" report to their offering. ... pharmaceutical excipients market is projected to reach USD 8.1 ... the forecast period 2016 to 2021. ...
(Date:6/23/2016)... June 23, 2016 Research and Markets ... Medical Market Analysis 2016 - Forecast to 2022" report ... The report contains up to date financial data derived from ... of major trends with potential impact on the market during ... market segmentation which comprises of sub markets, regional and country ...
Breaking Medicine Technology: